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Monoclonal antibodies are playing an increasing role in both human and animal
health. Different strategies of protein and chemical engineering, including humanization
techniques of non-human antibodies were applied successfully to optimize clinical
performances of antibodies. Despite the emergence of techniques allowing the
development of fully human antibodies such as transgenic Xeno-mice, antibody
humanization remains a standard procedure for therapeutic antibodies. An important
prerequisite for antibody humanization requires standardized numbering methods to
define precisely complementary determining regions (CDR), frameworks and residues
from the light and heavy chains that affect the binding affinity and/or specificity of the
antibody-antigen interaction. The recently generated deep-sequencing data and the
increasing number of solved three-dimensional structures of antibodies from human and
non-human origins have led to the emergence of numerous databases. However, these
different databases use different numbering conventions and CDR definitions. In addition,
the large fluctuation of the variable chain lengths, especially in CDR3 of heavy chains
(CDRH3), hardly complicates the comparison and analysis of antibody sequences and
the identification of the antigen binding residues. This review compares and discusses
the different numbering schemes and “CDR” definition that were established up to date.
Furthermore, it summarizes concepts and strategies used for numbering residues of
antibodies and CDR residues identification. Finally, it discusses the importance of specific
sets of residues in the binding affinity and/or specificity of immunoglobulins.
Keywords: numbering scheme, complementary determining regions, antibody humanization, antigen binding
residue, antibody engineering
INTRODUCTION
In 1986, Muromonab-CD3 was the first monoclonal antibody (mAb) approved as a drug for human
therapy. This murine antibody directed against the T lymphocyte CD3 complex has been widely
used to prevent acute rejection in patients with organ transplants (1, 2). To date, the Food and
Drug Administration (FDA) has approved 71 mAbs1. These antibodies are mostly used against
1http://www.actip.org/products/monoclonal-antibodies-approved-by-the-ema-and-fda-for-therapeutic-use/
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cancers and immunological disorders (3). Furthermore,
multiple mAbs were proven to be efficient in the treatment
of various pathologies such as bone loss (Denosumab),
hypercholesterolemia (Evolocumab) or infectious diseases
(Raxibacumab, Palivizumab).
Over the last decade, with the emergence of the deep
sequencing techniques, an important number of new antibody
sequences have been reported. In addition, numerous 3D
structures of antibodies in complex with their target antigen
have been reported and have permitted statistical identification
of residues that are in direct contact with the antigen or that
affect the binding affinity (4–7). This has allowed approaching
the molecular basis of antigen-antibody interactions. Although
different bioinformatic tools, based on structural data, have
been developed to predict antigenic epitopes or the interaction
surface between a known antibody and its antigen (docking),
in silico approaches are currently not able to tailor de novo
the specificity of an antibody for a target antigen. In contrast,
in vivo immunization techniques or selection of antibodies from
combinatorial libraries by phage display are often used and
were proven to be efficient to obtain specific antibodies directed
against a given antigen of interest.
It is well documented that the structure of an immunoglobulin
forms a Y-shaped glycoprotein (∼150 kDa) that is composed of
two identical heavy and two identical light chains. These heavy
and light chains are each encoded by genes that have diverged
from the same ancestral gene. The variable domains of the
light and heavy chains are responsible for antigen binding while
the constant domains communicate with other components
of the immune system. Notably, besides these “standard”
immunoglobulins, camelids as well as some cartilaginous fish
express another type of antibody that is devoid of light
chain and is referred to as heavy-chain antibody (HcAb) or
immunoglobulin new antigen receptor (IgNAR), respectively.
These homodimeric antibodies are able to bind to their antigen
with similar affinity as conventional heterotetrameric antibodies.
In all cases, the variable domains of each chain contain three
hypervariable loops named complementary determining regions
(CDR-1,-2, and-3). The CDRs are separated by structurally
conserved regions called framework regions (FR-1,-2,-3, and-4)
that form a “core” β-sheet structure displaying these loops on the
surface of the variable domain. The length and composition of
the CDR sequences are highly variable, especially in the CDR3.
The origin of this diversity lies in the complexity of the genetic
mechanisms that generate the highly variable pool of antibodies
from a relatively small number of antibody genes. Variable
regions are assembled from two genes (V and J, for λ and κ light
chains) or three genes (V, D and J for heavy chains), following
the V(D)J recombinationmechanism. The joined regions are part
of CDR3. Further variability in CDR3 length and sequence is
introduced by the mechanisms that permit addition or deletion
of nucleotides in those junctions and by somatic hypermutations
in the recombined genes. The CDRs are often approximated
to the paratope of the antibody that interacts with the antigen
and therefore contains the antigen-binding residues. The present
review will demonstrate that this definition of the paratope is an
oversimplification and doesn’t exactly match with the reality.
Antibody engineering methods have triggered the attention
of many research groups as well as pharmaceutical companies.
Antibody engineering technologies are of increasing importance
in drug development and different biotherapeutics have been
developed, including exploitation of antibody fragments (8),
bispecific antibodies (9) or antibody-drug conjugates (10).
However, despite their increasing success in drug therapy,
mAbs commonly induce adverse events when injected into
patients, especially chimeric molecules that contain murine or
rat sequences (11) and can lead to the appearance of human
anti-globulin antibodies in the serum of the patients (12–14).
To overcome these problems, different strategies have been
developed that successfully reduce the immunogenicity of mAbs
and therefore the risk of immune adverse events. The simplest
approach to humanize a mAb consists in replacing the IgG
constant regions from animal origin with the corresponding
constant regions of human immunoglobulins. These, so-called,
chimeric antibodies still include the entire variable regions from
animal origin that are responsible for antigen binding. However,
in most cases, these variable regions contain immunogenic
regions that are sufficient to trigger adverse effects including
anaphylaxis (14). Therefore, further humanization methods
of the variable region were developed. In this context, the
CDR-grafting or Specificity Determining Residue (SDR)-grafting
have become widely used methods in the field. Briefly, these
approaches consist in replacing murine framework regions by
homologous regions from human origin (15, 16). These, so-
called, “reshaped mAbs” show fewer immunogenic epitopes
compared to chimeric antibodies. However, to reach a higher
degree of antibody humanization, a complete and precise
identification of immunogenic epitopes is required. In this
context, various approaches are available that have drastically
improved over the past few years, and have significantly refined
humanization methods. These approaches include surface
reshaping or veneering (17, 18), superhumanization (19), human
string content optimization (20) or combinatorial approaches
using phage-display libraries (21).
Unfortunately, even if these humanization techniques
produce mAbs with reduced immunogenicity, they frequently
lead to a loss in antibody affinity and/or specificity (22). In
most cases, the main causes for this affinity loss are attributed
to various factors such as imprecise definition of the CDR
sequences (23), inappropriate choice of the human framework
scaffold used for loop grafting and erroneous identification
of structural corresponding residues from different species.
Indeed, the antibody engineering techniques require an accurate
identification of CDRs, antigen-binding residues as well as
structural corresponding residues. Therefore an appropriate and
standardized numbering scheme is crucial. Unfortunately, the
establishment of a robust inter-species numbering convention
is extremely challenging, especially given the high variability in
CDR lengths and sequences.
The present review is divided into two parts. The first
part describes and discusses the different numbering schemes
of the variable regions established up to date. The second
part compares the different CDR definitions and discusses the
different residues involved in antigen-binding as well as a
Frontiers in Immunology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 2278
Dondelinger et al. V-Region Numbering and CDRs
number of framework residues that, indirectly, affect the binding
affinity of immunoglobulins. Finally, we discuss and suggest a
general approach for antibody humanization. Adequate antibody
numbering and annotation is of crucial importance in the field
of antibody engineering and it will strongly advance monoclonal
antibody-based human drug development.
NUMBERING SCHEMES OF ANTIBODY
VARIABLE DOMAINS
Antibody engineering methods require precise identification of
the residues that have an impact on the interaction and/or affinity
of the antibody for its target antigen. For example, as mentioned
above, CDR-grafting aims to decrease the immunogenicity of
non-human antibodies by engineering the variable regions
directed against the target antigen. This method requires an
accurate identification of the CDRs and therefore an adequate
alignment of antibody sequences from human and non-human
species. Moreover, as discussed later in this review, it has been
shown that residues from the framework regions might also
exert a strong impact on the antibody affinity (24). Thus, the
precise identification of corresponding positions in human and
animal immunoglobulin chains is essential. However, the use
of different amino acid numbering schemes currently available
in the literature is confusing and might lead to aberrant
identification of framework and CDR residues. Therefore, it is
of crucial importance to understand the different numbering
schemes and, consequently, being able to compare them. The
following section is dedicated to the description of the different
numbering schemes that are compared and summarized in
Table S1.
Kabat Numbering Scheme
Over the past decades, sequencing and crystallization of
antibodies resulted in significant increase of various sequence
and structure databases, which made the comparison of the
variable regions from human and animal immunoglobulins
possible. In 1970, Kabat and Wu aligned 77 Bence-Jones protein
and immunoglobulin light chain sequences in order to study the
statistical variability in amino acid composition at the sequential
positions of the variable antibody regions. They defined the
“variability parameter” as the number of different amino acids
at a given position divided by the frequency of the most
occurring amino acid at that position. This analysis revealed
three hypervariable regions in the variable region of the light
chains. The presence of highly conserved residues was also
demonstrated, such as the two cysteines that form a disulphide
bridge at the inner core of the immunoglobulin domain and
a tryptophan residue located immediately after CDRL1 (25).
Likewise, three corresponding hypervariable regions were also
identified in the variable heavy chain domain (26, 27). Kabat and
Wu postulated that these hypervariable regions would cluster at
one side of the folded domain to form a surface responsible for
specific antigen recognition and referred to these hypervariable
regions as “Complementarity Determining Regions” “CDR”-1,-
2, and-3. This hypothesis was later confirmed and further
investigated to distinguish antigen-contacting or conformational
important residues within these CDRs (28).
In 1979, Kabat et al. were the first to propose a standardized
numbering scheme for the variable regions of immunoglobulins
(29). In their compilation of “Sequences of Proteins of
Immunological Interest” (30), the amino acid sequences of the
variable region of the light (λ, κ) and heavy chain of antibodies,
as well as the variable region of T cell receptors (α, β, γ, δ)
were aligned and numbered. They observed that the analyzed
sequences exhibited variable lengths and that gaps and insertions
could only be included at precise positions. Interestingly, the
points of insertion were located inside the CDRs, except for
CDRL2, but also at some positions inside the framework regions
(30). In the numbering schemes, these insertions are identified
and annotated with letters (e.g., 27a, 27b. . . ). It is also noticeable
that residue L10 is absent in all the λ light chains, while λ and
κ chains are being coded by two different genes, located on
different chromosomes. Over the last decades, the accumulation
of sequences resulted in the creation of the KABATMAN
database (31).
Although the Kabat numbering scheme is often considered
as the standard that is widely adopted for numbering antibody
residues, it has some important limitations. Firstly, this scheme
was built on the alignments of a limited number of sequences
from antibodies with the most common sequence lengths.
Consequently, sequences with unconventional insertions or
deletions in the CDRs or in the framework regions were not
included. Therefore, the original Kabat scheme ignores antibody
chains of unconventional lengths, with unique insertions or
deletions. However, a useful numbering tool namedABnum2 that
numbers the amino acid sequences of variable domains according
to a much larger and regularly updated database (Abysis3),
takes into account insertions of variable lengths, particularly
in CDR2 by adding an insertion point at position L54. The
second main limitation of the Kabat scheme is that it doesn’t
match very well with the 3D structure of antibodies. Indeed,
the hypervariable regions defined by Kabat do not exactly match
with the structural antigen-binding loops. The defined insertion
points in CDR-L1 (L27) and CDR-H1 (H35) do not fit with
their corresponding positions in the structures (Figure 1). In
other words, the corresponding residues (topologically aligned)
in crystal structures in CDR-L1 and CDR-H1 don’t share the
same number in the Kabat numbering scheme.
Chothia Numbering Scheme
In 1987, Chothia and Lesk introduced a structure-based
numbering scheme for antibody variable regions. They aligned
crystal structures of antibody variable regions, defined the loop
structures that form the CDRs and corrected the position
numbers of the insertion points inside CDRL1 and CDRH1
so that they better fit their topological positions (Figure 1)
(32). Furthermore, they classified the CDR loops of heavy and
light chains in a small number of conserved structures, called
“canonical” classes (32–34) that will be discussed later.
2http://www.bioinf.org.uk/abs/abnum/
3http://www.bioinf.org.uk/abysis/
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FIGURE 1 | CDRL1 amino acid insertion positions according to the Kabat and Chothia numbering scheme for light chain variable domains of protein databank (PDB)
structures 1igm and 2imm. (A) Amino acid sequence of the 1igm and 2imm CDR1L according to the Kabat or Chothia numbering scheme. The insertion of amino
acids from longer loops is placed behind L27 (magenta) and denoted by ‘27a to 27f’ according to Kabat’s numbering; whereas they are placed behind L30 (blue)
according to Chothia’s numbering scheme. The structurally aligned position L31 is shown in red. (B) Ribbon representation of the superposition of the CDRL1 loops of
1igm and 2imm from amino acids L24 to L34. The color code is as in (A) and the additional amino acids of 2imm in CDRL1 (L27a to L27f) according to Kabat
numbering are shown in yellow. (C) Same structural superposition as in (B) except that the yellow colored supplementary amino acids and the blue amino acid
position is according to Chothia’s numbering scheme.
Based on the alignment of antibody structures, the Chothia
numbering scheme shifts the point of amino acid insertion
from position L27 to L30 and from position H35 to H31. It
is worth mentioning that the Chothia CDR definition ensures
a better correspondence to the structural loops. The loop
structure of CDRH3 identified by Chothiamatches well the Kabat
hypervariable region. In contrast, the other loops are shorter
than the hypervariable sequences defined by Kabat, except for
CDRH1 which extends from H26 to H32. In any case, the CDRs
defined on the hypervariable amino acids according to Kabat and
based on loop topology in Chothia’s nomenclature have for some
CDR’s a shifted location and/or comprise deviating loop lengths
(Figure 2).
The Chothia numbering scheme possesses themain advantage
that topologically aligned residues from different antibodies are
localized at the same position number and that the Chothia
CDR definition corresponds in most antibody sequences to the
structural antigen-binding loops. However, confusion can also
arise given the limited use of this numbering scheme compared
to the Kabat or the IMGT numbering schemes (see below).
Furthermore, a later study published by Chothia et al. changed
the insertion point in CDR L1 from residue L30 to L31 (34).
However, while investigating the conformation of the antigen-
binding loops, of antibodies present in larger databases, they
returned to the initial L30 position in 1997 (33). In a similar way,
they initially defined an insertion point at position L93 in λ light
chains (32) that was shifted to position L95 in their subsequent
study (33). Finally, an important limitation of this numbering
scheme is due to the use of the most common CDR sequence
lengths, like the Kabat numbering scheme, and therefore the
Chothia scheme ignores sequences with unconventional length.
However, similarly to the Kabat numbering scheme, this system
could be optimized by defining new insertion points.
Martin Numbering Scheme
In a study published in 2008, Martin et al. focussed on
the structural alignment of different framework regions of
unconventional lengths (35). They highlighted residues that
are absent in most sequences and structures and therefore
the authors defined these as deletion positions. By analyzing
sequences and structures, they also proposed a correction of the
insertion point within the framework region 3 of the heavy chain
domain from position H82 to H72. In addition and by analogy
with CDRH2, they amended the position of the insertion point
for the CDRL2 that locates now at position L52. Finally, they
used the numbering software, ABnum, mentioned earlier and
recommended a new numbering scheme that consists of the
Chothia numbering system corrected by the ABnum software.
Indeed, this software uses the much larger Abysis database,
which integrates sequences from Kabat, IMGT, and the PDB
databases. For this reason, the ABnum program defines a novel
insertion/deletion position at position H6 in the Chothia and
Kabat numbering schemes (6). The Martin numbering scheme
corrects this point of insertion and shifts it toward position H8.
The Martin numbering scheme should be considered as the
most recent version of the Chothia numbering. By analyzing
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FIGURE 2 | Disparity in CDR definitions according to Kabat (hypervariable
regions) (A, C) and Chothia (structural loops) (B, D) shown on the 1kiq domain
structures. The variable domain 3D structures of the light (A, B) and heavy (C,
D) chain are represented in cartoon with the frameworks in gray and CDR
highlighted in red according to Kabat (A, C) and Chothia (B, D) numbering
scheme.
sequences and structures on larger databases, it corrects insertion
positions, defines new ones and highlights the location of
deletions in order to fit better the topological positions of
residues.
Gelfand Numbering Scheme
Another interesting numbering method that has been used in a
few studies is the one described by Gelfand et al. (36–39). This
numbering system results in a relatively complex nomenclature.
The variable chain sequences are divided into 21 fragments
termed “words,” each of these “words” matches with a secondary
structure element (a strand or a loop). The strands are defined
by a letter in alphabetical order (e.g., A, B, C) and the loops by
two letters that corresponds to the neighboring strands (e.g., AB,
BC. . . ). However, there are two exceptions in this terminology:
the three N-terminal residues of the variable chain (named
OA since they are not part of the first β-strand) and the loop
connecting the B and C strands, which has a ‘two span bridge’
conformation with one residue deeply inserted into the structure
(40) (Figure 3). This loop is divided into two words named
BC and CB. This numbering system does not include gaps or
deletion points but permits a precise comparison of secondary
structures (loops and strands) between aligned sequences. It’s also
noticeable that the Gelfand definition of several loops does not
exactly correspond to Chothia’s definition of loops.
IMGT Numbering Scheme
In 1997, Lefranc et al. introduced a new and standardized
numbering system for all the protein sequences of the
FIGURE 3 | Representation of the “two-span-bridge” conformation of CDRL1
present in the 2fb4 antibody structure. The two-span-bridge is represented in
gray and the bordering strands are shown in yellow (A, B). (A) Shows the
isolated loop with an Ile side chain (colored red) pointing inwards the loop
structure. (B) The complete domain showing how the Ile penetrates deeply
into the core of the light chain variable domain making hydrophobic
interactions with neighboring residues organized in a pocket (purple spheres).
immunoglobulin superfamily, including variable domains from
antibody light and heavy chains as well as T cell receptor chains
from different species (41, 42). Their numbering scheme was
based on amino acid sequence alignment of the germ-line V
genes. Consequently, the amino acid sequence and numbering
stops where CDR3 should start. Later on, the authors extended
their numbering scheme to the entire variable domains and
developed various tools to analyze the full-length sequences (43).
IMGT possesses its own definitions of the framework regions
(named FR-IMGT) and CDR (named CDR-IMGT).
The IMGT numbering method counts residues continuously
from 1 to 128 based on the germ-line V sequence alignment.
Thus, it avoids the use of insertion codes, except between
position 111 and 112 for CDR3-IMGT with more than 13 amino
acids. Conversely, no number is attributed when a residue is
missing in a particular sequence. For example, in a 6 amino acid
long CDR1-IMGT, residue #27 is followed by residue #34 (and
residue numbers #28–#33 are absent). An example of alignment
according to Kabat, Chothia and IMGT numbering schemes is
shown in Figure 4.
IMGT is the primary reference in immunogenetics and
immuno-informatics. Its conventions, including its amino acid
numbering method, have been recognized and are currently
used by the World Health Organization—International Union of
Immunological Societies. This numbering method has the main
advantage that it is based on alignments of sequences from a
complete reference gene database (44, 45) including the whole
immunoglobulin superfamily. This has led to the development
of highly useful tools. For example, amino acid alignment and
numbering can be performed by the IMGT/DomainGapAlign
(46). This tool also enables to analyse sequence domain
polymorphisms by identifying the corresponding VDJ genes
coding for the variable region. It is coupled with another
interesting application known as IMGT- “Collier de Perles” (47)
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FIGURE 4 | Alignment of a nanobody sequence from the PDB (3dwt) according to Kabat, Chothia, and IMGT numbering schemes. In green are the cysteines forming
the conserved disulphide bond packed against a conserved tryptophan. In addition the conserved tryptophan118-glycine119 (IMGT numbering, also in green)
downstream of the CDR3H demarcates the start of the framework-4 region. The IMGT numbering scheme uses gaps (indicated in red), if a residue is absent at a
given position. Insertion positions are indicated in blue.
that allows to visualize at a glance the position of the amino acids
in a 2D representation, and also to delineate easily FR-IMGTs and
CDR-IMGTs.
However, due to the continuous numbering of the amino
acids along the sequence, the IMGT numbering scheme does not
allow an intuitive visualization of insertion positions, even for
the most common ones. For the same reason, this numbering
scheme is less flexible. Indeed, while in the Kabat and Chothia
numbering systems, positions of amino acid insertion points
are easily incorporated; it is more difficult to adapt the IMGT
scheme for potential sequences with new amino acid insertions.
It has to be noted that IMGT places all such insertions at the
end of the CDR, which doesn’t correlate with the antibody
structure. However, this problem has been corrected in the later
V-Quest software that places insertions in the middle of the
CDR-IMGTs, which matches better with the available structural
data (48).
Honneger’s Numbering Scheme (AHo’s)
The Honegger scheme numbers the variable domains of the
immunoglobulin superfamily in a homogenized format. This
system is based on structural alignments of the 3D structures
of the immunoglobulin variable regions covering the observed
length variation. It allows to define structurally conserved Cα
positions and therefore deduces appropriate framework regions
and CDR lengths (Figure 5) (49).
The Honegger numbering scheme (AHo’s) also defines
conserved residues (C23, W43, C106, G140) and gaps on
specific positions (#27-28, #36, #63, #123). The CDR1 has
a “two span bridge” conformation created by a conserved
hydrophobic residue at position #31 which is deeply inserted
into the structure and therefore divides the loop into two
distinct parts (40). The Honegger scheme describes two gap
regions located onto these two parts, one located in the first
part (#27 and 28) and the other one located in the second
part (#36). This convention respects the variability of insertions
present on both sides of the loop. Furthermore, two other
insertion points are located, respectively, at position #74 and
#75 to reflect the shorter C-terminal branch of the CDR2 loop
exhibited by T cell receptor α. Additional gap positions are
placed in the middle of the CDR-2 and-3 loops (Figure 5).
From further structure analysis, they proposed to shift the
insertion gap in Vκ chains initially located in position L10
to L8.
The main advantage of the Honegger numbering system
is that it is based on structural alignments and therefore it
matches better to antibody 3D structures features, in a similar
manner to the Chothia numbering scheme. In addition, as
mentioned for the IMGT scheme, AHo’s is well-suited for the
numbering of all proteins from the immunoglobulin superfamily
by including two gaps into CDR 1 and 2. However, similarly
to the IMGT scheme, the AHo’s can skip some numbers in
the sequential residue numbering which can be puzzling when
analyzing the sequence numbering. This numbering scheme is
also less flexible and adaptable to include immunoglobulins with
new or larger insertions. Although the observed length variability
was covered, it is possible that new insertion positions/lengths
could be found by taking into account a larger number
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FIGURE 5 | Representation of the Honneger numbering scheme. The amino acid positions that accommodate gaps are indicated in blue. The green positions
correspond to the structurally conserved residues whose Cα positions were used for structural superposition. This figure has been adapted from the study published
by Honneger et al. (49).
of structures. Furthermore, the most structurally conserved
positions were obtained from only 28 different structures.
Likewise, a better precision in defining the framework regions
could be reached by adapting the scheme specifically to the
variable region of a specific type of immunoglobulin (e.g.,
antibody).
Finally, the sequence numbering using the aHo’s can be
submitted to the PyigClassify server4. However, this server
doesn’t seem to take into account the two insertion positions
defined in the original paper (49).
4http://dunbrack2.fccc.edu/PyIgClassify/User/UserSequences.aspx
FINDING YOUR WAY AMONG THE CDRS
DEFINITIONS
CDR Definitions and Antigen Binding
Residues
CDRs are commonly considered as structured loops that are
involved in antigen binding and exhibiting a hyper-variable
amino acid composition. However, defining a CDR based on
antibody amino acid sequences can be complicated. Indeed, the
different numbering schemes presented in this review utilize
different definitions of CDR lengths. In addition, as shown earlier,
the Kabat (and IMGT) CDR definitions are based on sequence
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alignments while the Chothia CDR definition better reflects
the loop structure in antibodies’ 3D architecture. This lack of
agreement in defining precisely the CDR lengths and positions
is somehow unexpected since these regions were shown to be
responsible for the antigen-binding activity already a long time
ago (16). In order to address the disparity in CDR definitions,
several authors have taken into account the different possible
lengths for defining CDRs sequences. For example, North et al.
use longer sequences in their recent structural analysis of the
conformations of the CDR loops (50).
Furthermore, a high binding affinity reflects a very stable
antibody-antigen complex. This is accomplished by multiple
non-covalent bonds between amino acid residues of the paratope
and the epitope. However, it has been shown that only 20 to 33
% of the amino acids within the CDRs make direct contact with
the antigen (51). These residues, named “Specificity Determining
Residues (SDR)”, were first described by Padlan et al. (52). Their
results show that these SDRs are involved in the interaction
with the antigen and, in most cases, match with the most
variable positions present in the CDRs. Using this SDR concept,
MacCallum and co-workers suggested a new method to define
the CDRs and re-named the SDRs “contact residues”. They also
suggested that contact residues are more often located in the
center of the paratope and, as Chothia mentioned before, non-
contacting residues play a role in shaping the conformation of the
CDR loops and therefore orientate the contact residues optimally
for efficient and specific antigen binding. Finally, their study
showed that small antigens tend to bind a paratope with a more
concave interface (6), whereas long-convex-shaped paratopes
will be better suited to bind enzyme active sites and block
their catalytic activity. In this context, the use of nanobodies or
bovine antibodies that exhibit an extended length of CDR3 are
particularly interesting (53, 54).
Similarly, Ofran et al. used a multiple structural alignment
approach to identify the antigen binding residues of the
variable regions (55). They revealed that the antigen binding
residues show a particular amino acid composition, as previously
suggested by other groups (25, 56). In particular, tryptophan and
tyrosine residues are highly over-represented, whereas almost all
other residues are under-represented in all CDRs. Moreover, they
showed that conventional classical CDRs identification (Kabat,
Chothia, IMGT) could miss about 20% of the antigen binding
residues and suggested a new method for the identification
of the regions containing these antigen-binding residues. They
named these regions Antigen Binding Regions (ABRs) that
can be identified using the Paratome5 online tool. This server
identifies ABR by comparing the antibody sequence with a set
of antibody–antigen structural complexes (4, 55, 57). Another
useful alternative tool is proABC (http://circe.med.uniroma1.
it/proABC/). This software estimates the probabilities for each
residue to form an interaction with the antigen (58).
Another interesting approach was offered by Robin et al. (5)
studying the binding free energy of antibody-antigen complexes
using a computational alanine scanning method. They showed
that 80% of the binding free energy in the studied complexes
5http://ofranservices.biu.ac.il/site/services/paratome/
is clustered on a very limited number of interacting residues
(between 4 and 13). They highlighted 30 positions having major
contribution to the binding free energy, 27 of them being located
within the CDRs (using the Kabat definition) and the remaining
3 in the framework regions. All these positions are occupied by a
restricted panel of amino acids (Y, G, S, W, D, N) where aromatic
residues are the major contributors to the binding free energy.
Based on the identity of these residues, the nature of the antigen-
antibody interaction can be predicted and will be discussed later
(see discussion section). In their analysis, CDRH2 and CDRH3
include most of these residues while CDRL2 does not contribute
at all inmore than half of the investigated complexes. Finally, they
show that the Ab-Ag complex formation involves between 3 and
6 CDRs. They also confirmed their computational analysis using
experimental data from case studies (5).
Interestingly, a simple set of rules for Kabat and Chothia CDR
identification has been defined byMartin and implemented in the
ANTICALIGN software (59, 60).
Figure 6 illustrates the disparity in the CDR definitions.
This comparative alignment shows that CDRs defined with the
classical CDR definition (Kabat, Chothia, IMGT) should be
considered only as an approximation of the paratope. According
to all the concepts and observations described above, a residue
should be considered as part of the paratope if: (i) it is
in close contact with the antigen and/or; (ii) it significantly
and specifically contributes to the negative Gibbs energy
change occurring upon antibody-antigen complex formation.
Also, it should be noted that: (i) some contacting residues
may contribute minimally to the binding free energy and
even disfavor the complex formation and; (ii) that a residue
energetically important for binding to the cognate antigen
may not be important for the difference in affinity between
cognate and non-cognate antigens and, finally; (iii) a residue
crucial for antigen recognition may not be important for
binding free energy. Indeed, the paratope and its corresponding
epitope possess shape and chemical complementary surfaces.
This shape complementarity involves mainly aromatic residues
(W, F, Y) establishing van der Waals (pi-pi) or other hydrophobic
interactions. In contrast, stable Ag-Ab complexes, characterized
with low dissociation rate constants, are mostly attributed to
electrostatic interactions or hydrogen bonds involving charged or
polar side chain residues. Importantly, many residues included
within the CDRs are not directly in contact with the antigen,
but may also play an important role in the Ag-Ab interaction by
upholding the optimal conformation and orientation of nearby
interacting residues (33, 61).
Structural Classification of the CDRs
Ideally, an adequate definition of the CDRs should include all
the residues that form the surface of the paratope and that
interact with the epitope. A structural analysis of the CDRs is
therefore important. Chothia’s group classified the CDR loops
of heavy and light chains in a small number of conserved
structures, called “canonical” classes (32–34). This classification
system indicates that the CDRs of the light chain (CDR L1,
L2, L3) and the first two CDRs of the heavy chain (CDR H1,
H2) adopt only a few different structures. These structures seem
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FIGURE 6 | Alignment of residue positions of the CDRs within the light and heavy chain variable domains showing the disparity in the CDR definition according to the
different numbering schemes. The CDRs are highlighted in pale green. Amino acid insertion positions are indicated in red. In the Aho numbering system the
structurally conserved positions are colored in purple. For Martin’s CDR definition, the CDRs correspond to the antigen contact residues. Conserved residues
surrounding CDR 1 and 3 are indicated in green.
conditioned by the sequence length and presence of key amino
acids at hallmark positions. The authors identified that only
very few conserved residues (13 and 7 in the light and heavy
chains, respectively) found within the CDR and FR regions
are responsible for the conformations of the CDRs. However,
controversially, it seems that there is no obvious correlation
between the germ-line sequence of a CDR and its canonical class
(62), most likely because small sequence differences, including in
the framework regions, can impact the conformation of the CDRs
(63). Beside Chothia’s works, several other studies have enhanced
the structural clustering of these CDRs and the identification
of key residues impacting their conformations (50, 62, 64–66),
including the highly variable CDRH3 (67–69). An interesting
study published by De Genst et al. illustrates the relation between
sequence and structure of CDRs. Briefly, they showed that the
part of the CDR3 loop encoded by the same D gene in two
nanobodies adopts an identical structure and targets the same
epitope on the antigen (70).
In conjunction, these studies suggest that the structural
classification of the CDRs based on structure prediction from
the CDR sequences can be a very useful tool for antibody
engineering. A few online tools are available for this purpose
(71, 72)6,7. However, it is important to keep in mind that
residues from the framework regions can also influence the CDR
conformation as regularly discussed in this review.
INFLUENCE OF NON-CDR RESIDUES ON
THE ANTIBODY BINDING AFFINITY
It is now well-established and documented that non-CDRs
residues may play an important role in the binding affinity of the
antibody to its antigen (73), either by making direct contact with
the antigen (4, 61), by affecting the stability or flexibility of the
antibody or its antigen-binding loops (74), or by structuring the
CDR loop itself (75). Indeed, the residues from the framework
6http://dunbrack2.fccc.edu/pyigclassify/
7http://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/WelcomeSAbPred.php
regions can modulate the conformation of CDRs and therefore
affect the binding affinity. These residues were defined and
named “Vernier zone residues” and included amino acids located
in the framework regions just in the vicinity of the CDR loops
(75). Finally, non-CDR residues that influence the light and heavy
chain variable domain packing and orientation are also critical
for the antigen-binding affinity and, surprisingly, were often
ignored or neglected. Therefore, the amino acids of the Vernier
zone are incomplete and should be extended to include all the
residues located in the frameworks impacting the affinity of the
antibody. The next paragraph focuses on the residues located at
the interface between the VH and VL that alter the packing of
these domains and consequently, influence the topography of the
paratope.
Chothia et al. were the first to describe and analyse the packing
of the VL and VH domains (76). They highlighted the presence
of aromatic side chains that are involved in this interface, but
their analysis relied on only three antibody structures available
at that time. In 2010, Abhinandan and Martin made a more
comprehensive analysis of the diversity between VH and VL
packing angles including 567 antibody crystal structures. They
developed a method to predict the packing/orientation of the
heavy and light chain variable domains based on the presence of
specific amino acids located at the interface between these two
domains. In practice, they defined Cα atoms from structurally
conserved residues located at the interface between the VH and
VL domains. These atoms were then used to fit two regression
lines, one on the light and one on the heavy chain. The packing
angle value corresponds to the angle formed by these two fitted
vectors (Figure 7) and varies significantly from one antibody to
another (i.e., −31.0◦ to −60.8◦) with a mean of −45.6◦. Their
results suggest that the Chothia’s loop residues have only little
influence on this angle. In contrast, the authors identified 13
residues on the VH/VL interface that influence this packing angle
(77). A web tool named PAPS (Packing Angle Prediction Server)
is available online for the prediction of the packing angle and is
based on sequence homology8.
8http://www.bioinf.org.uk/abs/paps/
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FIGURE 7 | Representation of the VH/VL packing angle in the 1bgx structure.
(A) Shows the ribbon structure of the VH and VL in green and cyan,
respectively. The conserved residues used to define the packing angle are
shown in red. The regression lines, fitted on the Cα atoms of these residues
are shown in red dashed lines. (B) Shows the heavy chain variable domain of
the 1bgx structure and (C) shows the light chain variable domain of the 1bgx
structure.
More recently, Dunbar et al. (78) further characterized the
orientation of the variable domains. Indeed, one particular angle
might reflect more than one single possible orientation of the
VH and VL. Therefore, they developed a new method to describe
more precisely the VH/VL orientations by defining 5 different
angles and one distance. They also investigated positions in
the VH/VL interface and the residue identities influencing these
different angles and distance. They concluded that a particular
residue at a specific position might lead to more than one specific
VH/VL angle. They generated a new software named AB Angle
that is available online9, tomeasure the different angles from PDB
structures (78).
This VH/VL angulation influences also the relative position
of the CDRs and, consequently, the shape of the paratope. This
parameter can therefore have a strong impact on the binding
affinity. Indeed, the binding energy between two atoms is a
function of their distance following the Lennard-Jones relation.
A difference of a few Angstroms can strongly affect the value of
the binding free energy. Using right triangle simple trigonometry
and assuming a variable region length of 37 Å, a difference
of 1◦ between the VL/VH domains causes a displacement of
9http://www.stats.ox.ac.uk/~dunbar/abangle/
the atoms exposed on the CDR surfaces by about 0.6 Å. The
choice of the framework regions for humanization by the CDR-
grafting technique is therefore of crucial importance to maintain
affinity. For example, Nakanishi et al. showed a severe affinity
loss of a humanized antibody and restored the original affinity by
performing twomutations at the VH/VL interface (79). Similarly,
Bujotzek et al. performed antibody humanizations by selecting
human frameworks based on the predicted VH/VL orientation
and revealed a correlation between similar angles and affinity of
humanized antibodies (80).
This concept of packing angles is a critical aspect of antibody-
antigen interaction and the residues that modulate the VH/VL
orientation have therefore to be considered as elements that
introduce further diversity in the paratopes. Framework residues
affecting significantly the affinity are listed in Table S2.
DISCUSSION: IMPORTANCE OF AMINO
ACID NUMBERING AND CDR DEFINITIONS
IN ANTIBODY HUMANIZATION
To achieve a high affinity binding, the paratope and its
corresponding epitope must have large shape complementary
surfaces and, in addition, the contacting residues must establish
interactions that stabilize the complex. The parameters that
influence the shape diversity of the paratope are essentially the
CDR lengths and conformations (canonical classes) (32, 56, 64,
81), their relative orientations (77–79, 82) and the hydration shell
(solvation) of the binding interface (83). The binding of the two
complementary surfaces is mostly driven by aromatic residues
that establish van der Waals and hydrophobic interactions while
the strengthening of the complex involves rather electrostatic
interactions and hydrogen bonds established between side chains
of adequately positioned charged and polar residues.
An antibody humanization experiment attempts to
reconstitute the original paratope-epitope interactions, in
most cases, by grafting the CDRs of a non-human antibody to
a human antibody scaffold. This CDR-grafting or reshaping
method is often based on a simplified view of antigen-antibody
interaction that reduces the paratope to the 6 CDRs of the
antibody. Although, there is no general protocol to perform
an antibody humanization, since it is always a case-to-case
experiment, this section attempts to provide guidance in such
an exercise. Figure 8 summarizes and suggests a standardized
protocol to humanize antibodies from animal origins. Firstly, we
need to identify the CDRs within the loop of the donor antibody
from animal origin. Under the simplified assumption that the
paratope corresponds to the CDRs, it is recommended using the
Chothia’s CDR definition as they correlate very well with the
structural loops present in the variable regions. A few online
software tools are available for CDR structure prediction10,11
(72, 84) and classification12 (71). However, it is always best to
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FIGURE 8 | Representation of a standardized humanization protocol. Prediction tools are indicated in blue.
constituting the paratope will be included. Secondly, as discussed
repeatedly in this review, residues outside the classical CDR
definitions can also be part of the actual paratope. Different
studies can help to identify these residues, but unfortunately,
only one bioinformatical tool (Paratome) is currently available.
Finally, the relative orientation of the CDRs is also critical to
reconstruct the paratope surface and to position adequately
its antigen interacting residues. Hence, it is essential to choose
the most appropriate human VH and VL framework scaffolds.
Selecting this human antibody scaffold is probably as important
as the definition of the CDRs. The chosen human framework
scaffolds should exhibit the closest VH/VL angles compared
to those in the animal antibody for a correct positioning of
the CDRs in the reshaped construct. In this context, different
amino acid positions have been highlighted for their role in the
VH/VL angulation and various angle prediction software tools
are currently available. Thus, a reshaping effort to humanize
antibodies should be an effective “paratope grafting” experiment
rather than a “CDR-grafting.”
Noticeably, for all these purposes, it is important to align
the antibody sequences correctly and to identify precisely the
residues with superimposed positions in chains of different
origins. Therefore, the handling of the same and an adequate
numbering scheme that attributes an identical number of
residues (including fixed possible residue insertion points) to
occupy the same structural positions in the immunoglobulin
chains forms a prerequisite for all antibody engineering tasks. In
this respect, the enhanced Chothia’s (Martin’s) numbering system
is a bit easier to use since it identifies precisely insertion points
but, of course, this choice is quite subjective.
Another critical point is that the humanized antibodies
should not induce any adverse immune reaction in the
patient. Therefore, prediction of potential immunogenic epitopes
in the protein sequence should be performed. Briefly, this
adverse immune response takes place after internalization of
the antibodies by the antigen presenting cells. Antibodies are
digested in oligopeptides that bind to HLA-DR, HLA-DQ,
or HLA-DP molecules. These membrane protein complexes
Frontiers in Immunology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 2278
Dondelinger et al. V-Region Numbering and CDRs
bind specific oligopeptides and present them to lymphocytes T
helpers that activate the immune response. Nowadays, databanks
reporting the polymorphisms of these MHC-II molecule alleles
are available to predict the oligopeptide binding potential (85–
87). One of these is the Epivax web tool (88) that consists
in scanning a protein sequence for identifying putative T
cell epitopes. Identified antigenic sequences are predicted to
bind to HLA-II DR (or other HLA-II isotypes) proteins but
the program can also identify Treg epitopes that inhibit the
immunity response. This software offers to mutate one or more
amino acids in order to reduce the immunogenicity of a protein
sequence. Sequence immunogenicity is calculated and presented
in an “Epimatrix score” allowing to predict the immunogenicity
of a given amino acid sequence (89). Highlighting important
residues (for binding affinity/specificity, angulation, etc.) that
shouldn’t be mutated could improve this software. It is important
to realize, that in the case of antibodies, conflicts may arise
between maintaining a high affinity and a low immunogenicity.
This is one of the reasons why antibody humanization remains
challenging.
CONCLUSION
This review describes the different amino acid numbering
systems and CDR definitions that are currently available and
it highlights the importance of standardized numbering system
for antibody engineering strategies, especially for antibody
humanization tasks. Indeed, an effective amino acid numbering
system should be able to assign the same number of residues
to structurally aligned positions in antibodies from different
species. Although several numbering tools based on ever growing
databases are available online, it is recommended to compare
the different numbering systems as inaccuracies are still possible,
especially for variable antibody domains with unconventional
lengths.
Furthermore, the different CDR definitions and other
concepts, such as contact residues or antigen binding residues,
have been reviewed. In the context of antibody humanization
methods, paratope has been very often limited to the CDRs.
This approximation is useful as long as it permits the CDR-
grafting method to be an easy and generalizable tool for
humanization. In contrast, grafting contacting residues (even
these outside the CDRs) and/or residues having an impact on
the binding free energy would allow a better reconstitution
of the paratope. However, this approach is less convenient in
antibody humanization efforts because of the discontinuous
nature of the paratope combined with the experimental
approaches that require the precise determination of these
residues. Moreover, different studies that have analyzed the
angle between the light and heavy chain variable regions
have been described. In CDR-grafting or other antibody
humanization methods, residues affecting the VL/VH packing
angles should be considered in order to restore full binding
affinity. Finally, all of these concepts that are crucial for
the humanization of antibodies should be included in the
humanization process.
In summary, a precise identification of the paratope
established using an appropriate amino acid numbering scheme
is necessary to engineer humanized antibodies with high affinity,
stability and low immunogenicity. Designing a fully functional
paratope on another framework should not only be restricted
to grafting the antigen contacting and interacting residues, but
should also include the amino acids that assist in fixating the
antigen-binding loops and the residues at positions that affect the
relative orientation of the paired VL/VH. All these residues have
to occupy identical positions in the 3D structure.
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Table S1 | Alignment of the numbering systems described by Kabat, Chothia,
Martin (enhenced Chothia), Gelfand, IMGT and Honegger. VL states for variable
domains of light chains, VH for variable domains of heavy chains. IMGT and
Honegger (Aho) numbering systems do not take into account the nature (heavy or
light) of the chain. Insertion positions are highlighted in yellow. In the Aho
numbering scheme, these yellow residues correspond to the gap positions.
Deletion positions are in brackets (residue L 10 in lambda light chains, Martin
numbering scheme). CDR definitions are indicated in orange and framework
definitions in blue (IMGT and Aho schemes). The Gelfand numbering scheme is
divided in words (boxes) with the numbering below. For the Aho numbering
scheme, structurally conserved position are highlighted in green. Conserved
amino acids are indicated below the IMGT numbering scheme (Cys 23, Trp 41,
Leu 89, Cys 104, Phe/Trp 118, Gly 119).
Table S2 | Alignment of the numbering systems and CDR definitions described by
Kabat, Chothia, Martin (enhanced Chothia), IMGT and Honegger for light chains
and heavy chains. CDR definitions are indicated in orange. Residues impacting
affinity and/or angulation are indicated in red. The upper case letter refers to the
publication that describes the impact of the residue. These references are listed
below: Residues impacting the VH/VL angulation: (a)Abhinandan and Martin (35);
(b)Dunbar et al. (78); (d)Chailyan et al. (90), Residues impacting the affinity:
(c)Chatellier et al. (73); (e)Honegger and Plückthun (74); 30 positions impacting the
most the free binding energy are indicated in bolt and underlined (5).
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